Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis:new insights from subcutaneous semaglutide

Nonalcoholic fatty liver disease(NAFLD)is the commonest cause of chronic liver disease globally.It affects around 25%of the general adult population,and up to∼70-80%of patients,who are obese or have type 2 diabetes mellitus(T2DM)(1,2).Over the past decades,it has become increasingly clear that NAFLD is a“multisystem”disease,requiring a multidisciplinary and holistic approach(3).